39K Stock Overview
Engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Centogene N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.40 |
52 Week High | US$1.45 |
52 Week Low | US$0.38 |
Beta | -0.67 |
1 Month Change | -37.79% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -94.72% |
5 Year Change | n/a |
Change since IPO | -96.68% |
Recent News & Updates
Recent updates
Shareholder Returns
39K | DE Healthcare | DE Market | |
---|---|---|---|
7D | -37.8% | 3.6% | 1.6% |
1Y | n/a | 1.6% | 7.3% |
Return vs Industry: Insufficient data to determine how 39K performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how 39K performed against the German Market.
Price Volatility
39K volatility | |
---|---|
39K Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 6.5% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.6% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 39K's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 39K's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 444 | Kim Stratton | www.centogene.com |
Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics.
Centogene N.V. Fundamentals Summary
39K fundamental statistics | |
---|---|
Market cap | €10.76m |
Earnings (TTM) | -€40.09m |
Revenue (TTM) | €50.71m |
0.2x
P/S Ratio-0.3x
P/E RatioIs 39K overvalued?
See Fair Value and valuation analysisEarnings & Revenue
39K income statement (TTM) | |
---|---|
Revenue | €50.71m |
Cost of Revenue | €30.25m |
Gross Profit | €20.46m |
Other Expenses | €60.55m |
Earnings | -€40.09m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.44 |
Gross Margin | 40.35% |
Net Profit Margin | -79.06% |
Debt/Equity Ratio | -289.9% |
How did 39K perform over the long term?
See historical performance and comparison